成飞集成：10月24日召开董事会会议

Group 1 - The core point of the article is that Chengfei Integration (SZ 002190) held its 23rd meeting of the 8th board of directors on October 24, 2025, to review proposals including the expected increase in daily related transactions for 2025 [1] - For the first half of 2025, Chengfei Integration's revenue composition is 100% from the manufacturing sector [1] - As of the report date, Chengfei Integration has a market capitalization of 15.4 billion yuan [1] Group 2 - The article mentions that Chinese innovative drugs have generated $80 billion in overseas licensing this year, highlighting the hot secondary market in biomedicine [1] - A dialogue with Lu Gang, a partner at Chuangfang Investment, indicates that while the secondary market is thriving, the primary market is facing challenges in fundraising [1]